OA Journal of Case Reports最新文献

Dexmedetomidine infusions and phenobarbital in the treatment of an unusual presentation of benzodiazepine-resistant alcohol withdrawal 右美托咪定输注和苯巴比妥治疗苯二氮卓类抗酒精戒断的不寻常表现

OA Journal of Case Reports Pub Date : 2019-08-08 DOI: 10.33118/OAJ.REP.2019.01.011

N. Shah

{"title":"Dexmedetomidine infusions and phenobarbital in the treatment of an unusual presentation of benzodiazepine-resistant alcohol withdrawal","authors":"N. Shah","doi":"10.33118/OAJ.REP.2019.01.011","DOIUrl":"https://doi.org/10.33118/OAJ.REP.2019.01.011","url":null,"abstract":"Background: Alcohol withdrawal is a life-threatening condition characterized by a myriad of physiologic changes including tachycardia, hypertension, lowered seizure threshold, hallucinations, and potential for delirium tremens. Benzodiazepines remain the gold standard for treatment of alcohol withdrawal, although few studies have compared barbiturates to benzodiazepines as first-line treatment.\u0000Methods: This study is a single patient chart review.\u0000Results: Over the course of his hospital stay, in addition to receiving a continuous infusion of dexmedetomidine, the patient received a total of 389 mg lorazepam, 650 mg phenobarbital, 40 mg haloperidol, 25 mg quetiapine, 5 mg midazolam, and 75 mg diphenhydramine. \u0000Conclusion: Phenobarbital is an effective first line agent for management of alcohol withdrawal and may be a safer and more effective treatment with lower rates of intubation and shorter hospital stays than benzodiazepines. It is particularly successful in patients who require high doses of benzodiazepines or ICU admission. Furthermore, the role of dexmedetomidine infusions in alcohol withdrawal remains unclear but may play a critical role in mitigating tachycardia and hypertension though it poses a risk of bradycardia and hypotension.\u0000Keywords: Alcohol withdrawal, Dexmedetomidine, Precedex, Phenobarbital, Ativan, Lorazepam, CIWA, GABA channel.","PeriodicalId":309875,"journal":{"name":"OA Journal of Case Reports","volume":"57 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121247032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute unilateral reexpansion pulmonary edema after pleuropulmonary decortication 胸膜肺去皮术后急性单侧再扩张性肺水肿

OA Journal of Case Reports Pub Date : 2019-05-07 DOI: 10.33118/OAJ.REP.2019.01.010

B. Layla

引用次数: 0

Introduction of ultrasound at the bedside in the differential diagnosis of the pulmonary embolism as a cause of syncope 介绍床边超声在肺栓塞引起晕厥的鉴别诊断中的应用

OA Journal of Case Reports Pub Date : 2019-02-23 DOI: 10.33118/oaj.rep.2019.01.009

I. K. Iríbar Diéguez

引用次数: 0

Administration of crizotinib via jejunostomy tube: A case report 经空肠造口管给予克唑替尼1例

OA Journal of Case Reports Pub Date : 2018-07-25 DOI: 10.33118/OAJ.CLIN.2019.01.005

L. Knapen, A. Dingemans, S. Croes

{"title":"Administration of crizotinib via jejunostomy tube: A case report","authors":"L. Knapen, A. Dingemans, S. Croes","doi":"10.33118/OAJ.CLIN.2019.01.005","DOIUrl":"https://doi.org/10.33118/OAJ.CLIN.2019.01.005","url":null,"abstract":"Crizotinib is an orally available tyrosine kinase inhibitor, approved for treatment of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) rearrangement-positive non-small cell lung cancer (NSCLC). According to the product leaflet, crizotinib capsules should be swallowed whole, and should not be crushed, dissolved or opened. However, this manner of administration is not always possible. At present, literature is lacking regarding the absorption of crizotinib via percutaneous endoscopic jejunostomy (PEJ) tube. We report a case of a patient with ALK+ NSCLC who was administered crizotinib via PEJ tube. An adequate steady state crizotinib trough concentration was reached, resulting in a metabolic response. Safety for the caregiver was ensured since the administration of crizotinib was made without crushing or opening the capsule. This case supports the option for providing crizotinib via PEJ tube in patients who have ALK+ NSCLC and are unable to swallow whole capsules. This option might also apply to the administration of other ALK inhibitors.\u0000\u0000Keywords: Crizotinib, ALK inhibitor, percutaneous endoscopic jejunostomy tube, pharmacokinetics, non-small cell lung cancer.","PeriodicalId":309875,"journal":{"name":"OA Journal of Case Reports","volume":"51 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114086661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0